Revision as of 16:53, 20 August 2015 by WikiBot (talk | contribs) (Protected "Peginesatide": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

{{Drugbox | IUPAC_name = Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, diester with 21N6,21'N6-{[(N2,N6-dicarboxy-L-lysyl-β-alanyl)imino]bis(1-oxo-2,1-ethanediyl)}bis[N-acetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(1-naphthalenyl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-methylglycyl-L-lysinamide] cyclic (6→15),(6'→15')-bis(disulfide)[1] | image = | width = | alt = | imagename =

| tradename = Omontys | = Omontys | MedlinePlus = | licence_EU = | licence_US = OMONTYS | DailyMedID = | pregnancy_AU = | pregnancy_US = C | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | dependency_liability = | routes_of_administration = Subcutaneous, intravenous

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number = 913976-27-9 | CAS_supplemental =
1185870-58-9 (acetate) | ATCvet = | ATC_prefix = B03 | ATC_suffix = XA04 | ATC_supplemental = | PubChemSubstance = 124490628 | IUPHAR_ligand = | DrugBank = | ChemSpiderID = NA | UNII = | KEGG = | ChEBI_Ref =  ☑Y | ChEBI = 66889 | ChEMBL = | synonyms =

| chemical_formula = C231H350N62O58S6[C2H4O]n | molecular_weight = 45 kDa | smiles = | StdInChI = | StdInChI_comment = | StdInChIKey = | density = | solubility = | specific_rotation = }}

WikiDoc Resources for Peginesatide


Most recent articles on Peginesatide

Most cited articles on Peginesatide

Review articles on Peginesatide

Articles on Peginesatide in N Eng J Med, Lancet, BMJ


Powerpoint slides on Peginesatide

Images of Peginesatide

Photos of Peginesatide

Podcasts & MP3s on Peginesatide

Videos on Peginesatide

Evidence Based Medicine

Cochrane Collaboration on Peginesatide

Bandolier on Peginesatide

TRIP on Peginesatide

Clinical Trials

Ongoing Trials on Peginesatide at Clinical

Trial results on Peginesatide

Clinical Trials on Peginesatide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Peginesatide

NICE Guidance on Peginesatide


FDA on Peginesatide

CDC on Peginesatide


Books on Peginesatide


Peginesatide in the news

Be alerted to news on Peginesatide

News trends on Peginesatide


Blogs on Peginesatide


Definitions of Peginesatide

Patient Resources / Community

Patient resources on Peginesatide

Discussion groups on Peginesatide

Patient Handouts on Peginesatide

Directions to Hospitals Treating Peginesatide

Risk calculators and risk factors for Peginesatide

Healthcare Provider Resources

Symptoms of Peginesatide

Causes & Risk Factors for Peginesatide

Diagnostic studies for Peginesatide

Treatment of Peginesatide

Continuing Medical Education (CME)

CME Programs on Peginesatide


Peginesatide en Espanol

Peginesatide en Francais


Peginesatide in the Marketplace

Patents on Peginesatide

Experimental / Informatics

List of terms related to Peginesatide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Peginesatide(INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin.

It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. On February 23, 2013, Affymax and Takeda issued a press release indicating that they were recalling all batches of peginesatide from the market. Two randomized controlled trials published in 2013 found that the effectiveness of peginesatide was not inferior to epoetin for patients receiving dialysis (the EMERALD study), or to darbepoetin for patients with chronic kidney disease who were not receiving dialysis (the PEARL study). However, the safety endpoint of cardiovascular events and death was worse for peginesatide than for darbepoetin in the PEARL study.

Medical uses

The FDA approved the use of peginesatide for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.

Chemistry and mechanism of action

Peginesatide is a synthetic peptide, attached to polyethylene glycol ("PEGylated"). It mimics the structure of erythropoietin, the human glycoprotein which promotes red blood cell development.

Related drugs

The erythropoietin analogs currently used to treat anemia in the United States are epoetin alfa (sold under the names Procrit and Epogen) and darbepoetin alfa (which is a more glycosylated form of epoetin, sold under the name Aranesp). There are similar biologic agents, such as Mircera(a monoPEGylated erythropoietin-beta), sold by Roche in Europe, however United States patent law currently forbids their sale.